Journal of Antimicrobial Chemotherapy · 2022 · 17 citations · 26 references
PharmacyPharmacokineticsPharmacologyPharmacokinetic ModelingPopulation PharmacokineticsSepsisIntensive Care MedicinePharmacokinetics In Critical IllnessPharmacokinetics In Renal ImpairmentPharmacokinetics Of AntimicrobialsRenal ClearanceRenal Drug ClearancePharmacokinetics Of Antimicrobial AgentsPopulation Pharmacokinetic CovariatesPopulation Pharmacokinetic SimulationRenal Function CovariatesRenal Function EvaluationRenal Pharmacokinetic ModelingSepsis PharmacokineticsUrine Sample Collection
BACKGROUND: Imipenem and relebactam are predominantly excreted via glomerular filtration. Augmented renal clearance (ARC) is a common syndrome in critically-ill patients with sepsis, and sub-therapeutic antibiotic concentrations are of concern. Herein, we describe the pharmacokinetics of imipenem/relebactam in critically-ill patients with ARC. METHODS: Infected patients in the ICU with ARC (CLCR ≥ 130 mL/min) received a single dose of imipenem/cilastatin/relebactam 1.25 g as a 30 min infusion. Blood samples were collected over 6 h for concentration determination. Protein binding was assessed by ultrafiltration. An 8 h urine creatinine collection confirmed ARC. Population pharmacokinetic models with and without covariates were fit using the non-parametric adaptive grid algorithm in Pmetrics. A 5000 patient Monte Carlo simulation assessed joint PTA using relebactam fAUC/MIC ≥8 and imipenem ≥40% fT>MIC. RESULTS: Eight patients with ARC completed the study. A base population pharmacokinetic model with two-compartments fitted the data best. The mean ± SD parameters were: CL, 17.31 ± 5.76 L/h; Vc, 16.15 ± 7.75 L; k12, 1.62 ± 0.99 h-1; and k21, 3.53 ± 3.31 h-1 for imipenem, and 11.51 ± 4.79 L/h, 16.54 ± 7.43 L, 1.59 ± 1.12 h-1, and 2.83 ± 2.91 h-1 for relebactam. Imipenem/cilastatin/relebactam 1.25 g as a 30 min infusion every 6 h achieved 100% and 93% PTA at MICs of 1 and 2 mg/L, respectively. CONCLUSIONS: Despite enhanced clearance of both imipenem and relebactam, the currently approved dosing regimen for normal renal function was predicted to achieve optimal exposure in critically-ill patients with ARC sufficient to treat most susceptible pathogens.
26
Ghady Haidar, Nathan J Philips, Ryan K. Shields et al. · Clinical Infectious Diseases · 2017 · 276 citations · Full text
Augmented Renal Clearance in the ICU
Andrew Udy, João Pedro Baptista, Noelle Lim et al. · Critical Care Medicine · 2013 · 275 citations
Ivan Titov, Richard G. Wunderink, Antoine Roquilly et al. · Clinical Infectious Diseases · 2020 · 225 citations · Full text
Angela Huttner, Elodie von Dach, Adriana Renzoni et al. · International Journal of Antimicrobial Agents · 2015 · 220 citations